NOVO NORDISK A S - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act
Novo Nordisk strengthens executive team with new appointments | EuropaWire.eu | The European Union's press release distribution & newswire service
Novo Nordisk Stock Analysis - A Historical Danish Dividend Aristocrat
Novo Nordisk Is Focusing on These Strategic Areas in 2016
Novo Nordisk Dividende | Jung in Rente
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders | Business Wire
Contact our Novo Nordisk Investor Relations team
Novo Nordisk A/S 2022 Q2 - Results - Earnings Call Presentation (NYSE:NVO) | Seeking Alpha
Current Novo Nordisk dividend in March 2023
Novo Nordisk snaps up Dicerna for $3.3B, 2 years after liver research deal | S&P Global Market Intelligence
f6k_01.jpg
Novo Nordisk A focused global healthcare company with biotech expertise Investor Presentation Spring ppt download
image_001.jpg
Novo Nordisk Up After Strong Q3 Results; Raises Outlook - TipRanks.com
Novo Nordisk: Why I'm Buying This Diabetes Giant Despite The High P/E (NYSE:NVO) | Seeking Alpha
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates | Nasdaq
Contact our Novo Nordisk Investor Relations team
